Receipt of psychotherapy during a 12–month follow–up in patients with obesity and MDD
(comparison between propensity–score matched cohorts)

Population	Semaglutide cohort	Non–GLP–1RAs anti–obesity medications cohort		HR (95% CI)
Overall (n = 6,712/cohort)	8.9% (597)	11.0% (738)		0.81 (0.73–0.90)
Women (n = 4,962/cohort)	9.0% (445)	11.7% (579)		0.77 (0.68–0.88)
Men (n = 1,348/cohort)	10.0% (135)	13.1% (176)		0.75 (0.60–0.94)
age <= 45 years (n = 2,084/cohort)	11.9% (247)	14.0% (292)		0.85 (0.71–1.00)
age 46–64 years (n = 3,220/cohort)	7.8% (251)	10.4% (335)		0.75 (0.64–0.89)
age >=65 years (n = 1,404/cohort)	7.2% (101)	7.7% (108)		0.93 (0.71–1.23)
Black (n = 763/cohort)	10.2% (78)	9.3% (71)		1.11 (0.81–1.54)
White (n = 4,857/cohort)	9.1% (444)	11.8% (574)		0.77 (0.68–0.87)
No T2DM (n = 3,369/cohort)	8.6% (291)	11.8% (397)		0.74 (0.63–0.86)
T2DM (n = 3,271/cohort)	9.2% (302)	11.5% (376)		0.80 (0.69–0.93)

0.50 0.60 0.80 1.0 2.0
Hazard Ratio (HR)